Valeritas Holdings, Inc. (VLRX)
(Delayed Data from NSDQ)
$0.34 USD
+0.03 (9.85%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.34 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.34 USD
+0.03 (9.85%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.34 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Medtronic's All Business Lines Grow Despite Cost Concerns
by Zacks Equity Research
Within Diabetes group, Medtronic (MDT) is seeing a strong adoption of the Guardian Connect Smart CGM system.
Boston Scientific (BSX) Upbeat on Results of EVOLVE Study
by Zacks Equity Research
Boston Scientific (BSX) is hopeful about robust data outcome on DAPT study as the therapy duration might prove to be a superior treatment option.
Haemonetics Grows on Strong Plasma, Hemostasis Management
by Zacks Equity Research
Haemonetics (HAE) is gaining traction from a steady progress in Plasma franchise.
NuVasive Announces Innovations in Robotics Spine Surgery Line
by Zacks Equity Research
NuVasive (NUVA) aims to speed up the adoption of less invasive spine surgery through robotics.
GNC Holdings Inks Retail Partnership Deal to Grow in Brazil
by Zacks Equity Research
We consider this corporate deal in Brazil to be a strategic fit for GNC Holdings (GNC), which currently pulls out all the stops to fortify its global footprint.
Innovation Aids Genomic Health, Merger Procedure on Track
by Zacks Equity Research
Genomic Health (GHDX) is on course to realize its impending merger with cancer diagnostics major Exact Sciences, which will integrate brands like Cologuard and OncotypeDX.
Insulet (PODD) Scales 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Insulet (PODD) has various favorable factors to maintain the current high.
Valeritas Holdings, Inc. (VLRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Valeritas Holdings, Inc. (VLRX) delivered earnings and revenue surprises of 5.86% and 0.19%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Valeritas Holdings, Inc. (VLRX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Valeritas Holdings, Inc. (VLRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas
by Zacks Equity Research
Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas
Use Rising P/E Strategy to Buy 5 Winning Stocks
by Sanghamitra Saha
Cross the age-old barrier of low P/E investing, bet on these five stocks that boast rising P/E.
Valeritas Holdings, Inc. (VLRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Valeritas Holdings, Inc. (VLRX) delivered earnings and revenue surprises of 0.00% and 3.27%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Valeritas Holdings, Inc. (VLRX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Valeritas Holdings, Inc. (VLRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Small-Cap Stocks That Are Set to Explode Higher in 2019
by Urmimala Biswas
With no near-term respite in sight from the ongoing U.S.-China tariff tension, investors are now shifting their focus to smaller domestic companies.
The Zacks Analyst Blog Highlights: Chimerix, MacroGenics, Rockwell Medical, TG Therapeutics and Valeritas
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chimerix, MacroGenics, Rockwell Medical, TG Therapeutics and Valeritas
5 Beaten-Down Medical Product Stocks to Rebound in 2019
by Nabaparna Bhattacharya
As the Medical product industry is witnessing temporary sluggishness, a sneak peek into some possible outperformers in 2019 could be a great idea for investors.